Gabriel Helmlinger

5.3k total citations · 3 hit papers
65 papers, 4.1k citations indexed

About

Gabriel Helmlinger is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Gabriel Helmlinger has authored 65 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 14 papers in Surgery. Recurrent topics in Gabriel Helmlinger's work include Lung Cancer Treatments and Mutations (11 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Diabetes Treatment and Management (7 papers). Gabriel Helmlinger is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Diabetes Treatment and Management (7 papers). Gabriel Helmlinger collaborates with scholars based in United States, Russia and Sweden. Gabriel Helmlinger's co-authors include Rakesh K. Jain, Marc Dellian, Fan Yuan, Paolo A. Netti, Robert J. Melder, Robert M. Nerem, David W. Boulton, Peter J. Greasley, Karen Melissa Hallow and John J.V. McMurray and has published in prestigious journals such as Nature, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Gabriel Helmlinger

63 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation

1997 1.3k citations Gabriel Helmlinger, Fan Yuan et al. profile →
Solid stress inhibits the growth of multicellular tumor spheroids

1997 648 citations Gabriel Helmlinger, Paolo A. Netti et al. Nature Biotechnology profile →
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis

2017 355 citations Gabriel Helmlinger, Peter J. Greasley et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gabriel Helmlinger United States	23	1.7k	896	809	743	624	65	4.1k
Louis Gaboury Canada	38	2.1k 1.3×	1.0k 1.1×	1.2k 1.5×	1.3k 1.8×	223 0.4×	121	6.0k
Gang Cheng China	36	2.4k 1.5×	1.0k 1.1×	569 0.7×	1.3k 1.7×	679 1.1×	185	6.5k
Simon P. Robinson United Kingdom	49	2.0k 1.2×	798 0.9×	1.7k 2.1×	1.2k 1.6×	299 0.5×	243	8.1k
Yong Xu China	46	4.0k 2.4×	730 0.8×	1.2k 1.4×	785 1.1×	276 0.4×	192	6.8k
Jaetae Lee South Korea	38	2.3k 1.4×	772 0.9×	1.0k 1.3×	791 1.1×	128 0.2×	234	5.5k
Yicheng Ni Belgium	44	1.4k 0.8×	1.3k 1.5×	588 0.7×	1.2k 1.6×	223 0.4×	279	7.1k
Kurt R. Zinn United States	45	2.6k 1.6×	1.5k 1.7×	608 0.8×	1.6k 2.2×	214 0.3×	203	7.1k
Jianyu Rao United States	37	1.3k 0.8×	1.0k 1.2×	533 0.7×	846 1.1×	706 1.1×	146	4.4k
Yasuhiro Tamaki Japan	54	3.9k 2.3×	601 0.7×	2.2k 2.7×	2.5k 3.4×	514 0.8×	290	10.0k
Marc A. M. J. van Zandvoort Netherlands	32	1.4k 0.9×	526 0.6×	373 0.5×	237 0.3×	482 0.8×	85	4.4k

Countries citing papers authored by Gabriel Helmlinger

Since Specialization

Citations

This map shows the geographic impact of Gabriel Helmlinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriel Helmlinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriel Helmlinger more than expected).

Fields of papers citing papers by Gabriel Helmlinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabriel Helmlinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriel Helmlinger. The network helps show where Gabriel Helmlinger may publish in the future.

Co-authorship network of co-authors of Gabriel Helmlinger

This figure shows the co-authorship network connecting the top 25 collaborators of Gabriel Helmlinger. A scholar is included among the top collaborators of Gabriel Helmlinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriel Helmlinger. Gabriel Helmlinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Peskov, Kirill, et al.. (2025). Systematic review and quantitative meta-analysis of age-dependent human T-lymphocyte homeostasis. Frontiers in Immunology. 16. 1475871–1475871. 1 indexed citations

Zhudenkov, Kirill, et al.. (2025). A Systematic Comparative Analysis of Tumor Size Models Based on Erlotinib Clinical Data in Advanced NSCLC. CPT Pharmacometrics & Systems Pharmacology. 14(12). 1970–1981.

Peskov, Kirill, et al.. (2024). An integrative mechanistic model of thymocyte dynamics. Frontiers in Immunology. 15. 1321309–1321309. 1 indexed citations

Шульгин, Б. В., et al.. (2024). Optimization of the MACE endpoint composition to increase power in studies of lipid-lowering therapies—a model-based meta-analysis. Frontiers in Cardiovascular Medicine. 10. 1242845–1242845.

Helmlinger, Gabriel, et al.. (2024). Mathematical modeling in autoimmune diseases: from theory to clinical application. Frontiers in Immunology. 15. 1371620–1371620. 2 indexed citations

Helmlinger, Gabriel, et al.. (2024). Mathematical modeling of endogenous and exogenously administered T cell recirculation in mouse and its application to pharmacokinetic studies of cell therapies. Frontiers in Immunology. 15. 1357706–1357706. 3 indexed citations

Burga, Rachel A., Kyle D. Pedro, Jacques P. Tremblay, et al.. (2021). 1008P cytoTIL15: A novel TIL therapy for melanoma with superior potency and enhanced persistence without IL2 to improve safety & efficacy and expand patient eligibility. Annals of Oncology. 32. S852–S852. 1 indexed citations

Zhudenkov, Kirill, Robert S. Palmer, Alexandra Jauhiainen, et al.. (2021). Longitudinal FEV1 and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling. International Journal of COPD. Volume 16. 101–111. 7 indexed citations

Hallow, K. Melissa, David W. Boulton, Robert C. Penland, et al.. (2020). Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial. Journal of Pharmacology and Experimental Therapeutics. 375(1). 76–91. 10 indexed citations

10.

Voronova, Veronika, Victor Sokolov, Sara Straniero, et al.. (2020). A Physiology-Based Model of Bile Acid Distribution and Metabolism Under Healthy and Pathologic Conditions in Human Beings. Cellular and Molecular Gastroenterology and Hepatology. 10(1). 149–170. 33 indexed citations

11.

Voronova, Veronika, et al.. (2020). Quantification of Scheduling Impact on Safety and Efficacy Outcomes of Brain Metastasis Radio- and Immuno-Therapies: A Systematic Review and Meta-Analysis. Frontiers in Oncology. 10. 1609–1609. 9 indexed citations

12.

Zhudenkov, Kirill, et al.. (2019). Longitudinal tumor size and NLR as predictive factors of individual survival compared to their baseline values in patients with non-small cell lung cancer treated with durvalumab.. Journal of Clinical Oncology. 37(15_suppl). e20047–e20047. 1 indexed citations

13.

Mitchell, Pat, Bengt Hamrén, Gabriel Helmlinger, et al.. (2018). Integrating dose estimation into a decision‐making framework for model‐based drug development. Pharmaceutical Statistics. 17(2). 155–168. 1 indexed citations

14.

Kosinsky, Yuri, Simon J. Dovedi, Kirill Peskov, et al.. (2018). Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model. Journal for ImmunoTherapy of Cancer. 6(1). 17–17. 83 indexed citations

15.

Nyman, Elin, Gabriel Helmlinger, Bengt Hamrén, et al.. (2016). Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes. Interface Focus. 6(2). 20150075–20150075. 19 indexed citations

16.

Helmlinger, Gabriel, et al.. (2015). A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design. PLoS ONE. 10(3). e0118977–e0118977. 72 indexed citations

17.

Aksenov, Sergey, et al.. (2005). An integrated approach for inference and mechanistic modeling for advancing drug development. FEBS Letters. 579(8). 1878–1883. 25 indexed citations

18.

Helmlinger, Gabriel, Mitsuhiro ENDO, Napoleone Ferrara, Lynn Hlatky, & Rakesh K. Jain. (2000). Formation of endothelial cell networks. Nature. 405(6783). 139–141. 137 indexed citations

19.

Helmlinger, Gabriel, et al.. (1997). Solid stress inhibits the growth of multicellular tumor spheroids. Nature Biotechnology. 15(8). 778–783. 648 indexed citations breakdown →

20.

Dellian, Marc, Gabriel Helmlinger, Fan Yuan, & RK Jain. (1996). Fluorescence ratio imaging of interstitial pH in solid tumours: effect of glucose on spatial and temporal gradients. British Journal of Cancer. 74(8). 1206–1215. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact